drugset / Trial / NCT02521285

Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation

NCT02521285

Phase 2 Active not recruiting 21 enrolled National Cancer Institute (NCI)
RandomizedParallel-groupDouble-blindPrevention

Summary

This randomized phase II trial studies the safety of and how well aspirin works in preventing Barrett's esophagus from returning after it has been successfully eliminated by radiofrequency ablation. Studying samples of tissue from patients with Barrett's esophagus for the levels of a specific protein that is linked to developing Barrett's esophagus may help doctors learn whether aspirin can prevent it from returning after it has been successfully treated.

Timeline

Start
2016-01-15
Primary completion
2019-06-18
Completion
2027-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule 325 mg Oral